These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9263626)

  • 1. Histologic markers and long-term prognosis in breast cancer.
    Burtness BA
    Cancer J Sci Am; 1997; 3(4):211-2. PubMed ID: 9263626
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast cancer metastatic phenotype as predicted by histologic tumor markers.
    Heimann R; Ferguson D; Recant WM; Hellman S
    Cancer J Sci Am; 1997; 3(4):224-9. PubMed ID: 9263628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T; Khalifa A; Kamel AS
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for breast cancer.
    Beenken SW; Bland KI
    Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological, biochemical and morphological markers of breast disorders and of breast cancer.
    Leathem AJ
    Acta Histochem Suppl; 1990; 40():51-8. PubMed ID: 2091047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epidemiology of tumor markers in breast cancer management: prognostic markers.
    Page DL
    Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):101-4. PubMed ID: 8049630
    [No Abstract]   [Full Text] [Related]  

  • 7. Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer.
    Chivukula M; Brufsky A; Davidson NE
    J Natl Cancer Inst; 2009 May; 101(10):698-9. PubMed ID: 19436037
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunomorphological characteristics of primary and recurrent breast neoplasms].
    Volchenko NN; Zavalishina LE; Shimbireva IB; Frank GA
    Arkh Patol; 1998; 60(4):4-7. PubMed ID: 9791688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of p53 for locoregional recurrence in mastectomy treated breast cancer patients].
    Rödel F
    Strahlenther Onkol; 2000 Dec; 176(12):586-7. PubMed ID: 11140156
    [No Abstract]   [Full Text] [Related]  

  • 10. A 65 kDa oncofetal protein (p65), proliferating cell nuclear antigen (PCNA) and Ki67 expression in breast cancer patients.
    Niewiadomska H; Mirowski M; Stempien M; Olborski B; Blonski JZ; Hanausek M; Wierzbicki R
    Neoplasma; 1998; 45(4):216-22. PubMed ID: 9890664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive and prognostic factors in breast cancer evaluated by immunohistological methods].
    Sinn HP; Magener A; Dürr F; Harcos A; von Minckwitz G
    Verh Dtsch Ges Pathol; 2001; 85():200-5. PubMed ID: 11894398
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative predictive value of three prognostic markers--S-phase fraction, PCNA and Mitotic count on axillary lymph node metastasis in carcinoma breast.
    Pervez S; Khan MN; Nasir MI
    J Ayub Med Coll Abbottabad; 2007; 19(1):3-5. PubMed ID: 17867469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors.
    Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Markopoulos C; Gogas J; Kittas C
    Cancer; 2002 May; 94(9):2454-65. PubMed ID: 12015771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Utility and specificity of markers of breast cancer].
    Hurlimann J
    Arch Gynecol Obstet; 1990; 247 Suppl():S86-90. PubMed ID: 2085280
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prognostic and predictive factors in breast cancer].
    Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
    Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Voduc D; Nielsen TO; Cheang MC; Foulkes WD
    Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
    Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Tsukiyama A; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Mod Pathol; 2003 Apr; 16(4):309-14. PubMed ID: 12692195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.